Novel biomarkers added to movement disorders profile - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
Melanoma panel provides more tumor information - Insights
In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.
Comprehensive panel boosts GIST diagnosis sensitivity - Insights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) - Insights
Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide...
Communiqué Archives - Page 2 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
Testing Archives - Page 2 of 26 - Insights
Skip to Content MayoACCESS MayoLINK...
Testing Archives - Page 3 of 26 - Insights
Skip to Content MayoACCESS MayoLINK...
Testing Archives - Page 4 of 26 - Insights
Skip to Content MayoACCESS MayoLINK...
Urinary ammonium testing - Insights
John Lieske, M.D., discusses Mayo Clinic Laboratories' urinary ammonium testing. A test that takes the guesswork out of determining acid base disorders by giving nephrologists a true understanding of a patient’s true urinary ammonium level.
Our experts discuss the latest from Mayo Clinic Laboratories, so you can stay up to date on the most advanced diagnostics and newly developed tests. Note: Podcasts will not play back on Internet Explorer. Please use an alternative web...